Cargando…
Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
Noninvasive circulating tumor DNA (ctDNA) can be used to predict breast cancer recurrence and prognosis. In this study, we detected 226 and 114 somatic variants in tumor DNA from 70 primary breast cancer (PBC) patients (98.59%) and ctDNA from 48 patients (67.61%), respectively. Gene frequencies of t...
Autores principales: | Zhou, Yidong, Xu, Yaping, Gong, Yuhua, Zhang, Yanyan, Lu, Yaping, Wang, Changjun, Yao, Ru, Li, Peng, Guan, Yanfang, Wang, Jiayin, Xia, Xuefeng, Yang, Ling, Yi, Xin, Sun, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487710/ https://www.ncbi.nlm.nih.gov/pubmed/30672098 http://dx.doi.org/10.1002/1878-0261.12456 |
Ejemplares similares
-
The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017) -
Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018) -
Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019) -
The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022) -
Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)